MY-875
目录号 : GC66457
MY-875 是一种竞争性的微管蛋白聚合 (microtubulin polymerization) 抑制剂, IC50 值为 0.92 μM。MY-875 通过靶向秋水仙碱结合位点抑制微管蛋白聚合，同时可以激活 Hippo 通路。MY-875 可以诱导细胞凋亡 (apoptosis)，具有抗癌活性。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MY-875 is a competitive microtubulin polymerization inhibitor with an IC50 value of 0.92 μM. MY-875 inhibits microtubulin polymerization by targeting colchicine binding sites and activates the Hippo pathway. MY-875 induces apoptosis and has anticancer activity[1].
MY-875 (0-80 μM, 48 h) has significant anti-proliferative activity against cancer cells[1].
MY-875 (1-10 μM) can inhibit microtubule protein polymerization with an IC50 value of 0.92 μM while inhibiting alkylation of β-tubulin and the formation of EBI-β-tubulin adduct bands in a dose-dependent manner[1].
MY-875 (0-45 nM, 48 h) can induce the phosphorylation state of MST (Ste20-like kinases) and LATS (large tumor suppressor kinases), leading to YAP (Yes-associated protein) degradation in a dose-dependent manner[1].
MY-875 (0-45 nM, 24 h) significantly inhibits cell colony-forming ability, arrests cells in the G2/M phase and induces cell apoptosis in a dose-dependent manner[1].
Cell Proliferation Assay[1]
| Cell Line: | MGC-803, HCT-116, KYSE450, HGC-27, SGC-7901cell lines |
| Concentration: | 0-80 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited the proliferation of MGC-803, HCT-116, KYSE450, HGC-27 and SGC-7901 cells with the IC50 values of 0.027, 0.055, 0.067, 0.033 and 0.025 μM, respectively. Showed strong inhibitory effect on other tumor cell lines with the IC50 values less than 0.1 μM, such as DU145, A549, MCF-7, etc. |
Cell Cycle Analysis[1]
| Cell Line: | MGC-803, SGC-7901 cell lines |
| Concentration: | 0-45 nM |
| Incubation Time: | 24 hours |
| Result: | Increased the percentage of cells in G2/M phase from 19.38% to 76.97% in MGC-803 cells and from 7.04% to 80.89% in SGC-7901 cells, respectively at 45 nM. |
Apoptosis Analysis[1]
| Cell Line: | MGC-803, SGC-7901 cell lines |
| Concentration: | 0-45 nM |
| Incubation Time: | 48 hours |
| Result: | Induced apoptotic cells from 21.96% to 76.08% in MGC-803 cells and from 9.28% to 63.51% in SGC-7901 cells, respectively at 45 nM. Reduced expression of anti-apoptotic proteins c-IAP1, Bcl-xL and Mcl-1. |
| Cas No. | SDF | Download SDF | |
| 分子式 | C21H25NO6 | 分子量 | 387.43 |
| 溶解度 | DMSO : ≥ 250 mg/mL (645.28 mM) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5811 mL | 12.9056 mL | 25.8111 mL |
| 5 mM | 0.5162 mL | 2.5811 mL | 5.1622 mL |
| 10 mM | 0.2581 mL | 1.2906 mL | 2.5811 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway
Eur J Med Chem 2022 Oct 5;240:114583.PMID:35834904DOI:10.1016/j.ejmech.2022.114583
Novel N-benzylarylamide saderivatives were designed and synthesized, and their antiproliferative activities were explored. Some of 51 target compounds exhibited potent inhibitory activities against MGC-803, HCT-116 and KYSE450 cells with IC50 values in two-digit nanomolar. Compound I-33 (MY-875) displayed the most potent antiproliferative activities against MGC-803, HCT-116 and KYSE450 cells (IC50 = 0.027, 0.055 and 0.067 μM, respectively) and possessed IC50 values ranging from 0.025 to 0.094 μM against other 11 cancer cell lines. Further mechanism studies indicated that compound I-33 (MY-875) inhibited tubulin polymerization (IC50 = 0.92 μM) by targeting the colchicine bingding site of tubulin. Compound I-33 (MY-875) disrupted the construction of the microtubule networks and affected the mitosis in MGC-803 and SGC-7901 cells. In addition, although it acted as a colchicine binding site inhibitor, compound I-33 (MY-875) also activated the Hippo pathway to promote the phosphorylation status of MST and LATS, resulting in the YAP degradation in MGC-803 and SGC-7901 cells. Due to the degradation of YAP, the expression levels of TAZ and Axl decreased. Because of the dual actions on colchicine binding site and Hippo pathway, compound I-33 (MY-875) dose-dependently inhibited cell colony formatting ability, arrested cells at the G2/M phase and induced cells apoptosis in MGC-803 and SGC-7901 cells. Moreover, compound I-33 (MY-875) could regulate the levels of cell cycle and apoptosis regulatory proteins in MGC-803 and SGC-7901 cells. Furthermore, molecular docking analysis suggested that the hydrogen bond and hydrophobic interactions made compound I-33 (MY-875) well bind into the colchicine binding site of tubulin. Collectively, compound I-33 (MY-875) is a novel anti-gastric cancer agent and deserves to be further investigated for cancer therapy by targeting the colchicine binding site of tubulin and activating the Hippo pathway.